• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BlueStar Genomics gains breakthrough nod for pancreatic cancer test

March 31, 2021 By Sean Whooley

Bluestar GenomicsBluestar Genomics announced today that it received FDA breakthrough device designation for its pancreatic cancer test.

San Diego-based Bluestar’s proprietary noninvasive pancreatic cancer detection test is designed for use with patients with new-onset diabetes, according to a news release.

The test uses a standard blood draw to assess whether an individual has an abnormal epigenomic and genomic signature associated with pancreatic cancer. The test uses Bluestar’s epigenomics technology platform that utilizes machine learning and the DNA-based 5-hydroxymethylcytosine (5hmC) biomarker to detect cancer, deviating from the standard liquid biopsy cancer tests.

Breakthrough designation was granted based on the evidence of the “uniqueness and robustness” of the company’s cell-free DNA cancer detection approach, the company said.

Bluestar Genomics plans to undertake a large clinical validation study to confirm the performance of pancreatic cancer detection in patients with new-onset diabetes, while the breakthrough nod allows for interaction with the FDA across development, validation and the approval processes.

“Late diagnosis deprives patients of potentially curative treatments and impacts survival rates,” Bluestar Genomics chief medical officer Dr. Kelly Bethel said in the release. “In contrast, when detected at an early stage, patients can be eligible for surgery, which can be curative. Therefore, early detection is paramount for giving patients better treatment options to potentially improve outcomes.”

“Currently, there are no screening methods to enable early detection of pancreatic cancer, while early, accurate detection has the potential to significantly improve prognosis by enabling better therapeutic options for patients,” added Bluestar chief executive & chief medical officer Samuel Levy. “With FDA’s designation, combined with continued collaboration with top research institutions, our goal is to accelerate important clinical validation studies to bring our pancreatic cancer test to market in the coming years and continue to extend our efforts toward a multi-cancer screening test.”

Filed Under: Clinical Trials, Diabetes, Diagnostics, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: Bluestar Genomics, FDA

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS